Crescom Co., Ltd. (CEO Jae Joon Lee), a
company with artificial intelligence technology specializing in musculoskeletal
medical image analysis, announced that it participated in the 78th Korean
Society of Radiology (KCR 2022) exhibition held at COEX in Samseong-dong, Seoul
from the 20th to the 24th September, and Crescom's medical solutions were
successfully promoted.
In particular, the 20th Asian Oceanian
Congress of Radiology (AOCR 2022) was held at the same time, and radiology
medical personnel from Korea and the Asia-Pacific region participated in the
exhibition.
At the AOCR 2022 & KCR 2022 exhibition,
Crescom exhibited three AI imaging solutions, including ▲ bone age (growth
plate) analysis solution MediAI-BA, ▲ scaphoid fracture readable solution
MediAI-FX, and ▲ knee arthritis severity analysis solution MediAI-OA, to
introduce the achievements of Crescom to many radiologists in Korea and abroad.
Crescom's MediAI-BA is a hybrid analysis
method of GP and TW3, a bone-age reading technique, and helps doctors more accurately
and conveniently read bone age. MediAI-FX is the world's first licensed medical
device that can read scaphoid fractures, which are especially difficult to read
among wrist fractures. MediAI-OA is a software that automatically quantifies
and analyzes the severity of arthritis based on the KL grade for knee X-Ray
images, and is currently in the clinical trial stage.
Crescom is actively collaborating overseas
partners and licensing overseas to enter overseas markets. In addition, by
researching medical AI solutions with major general hospitals in Korea, Crescom
is continuously collaborating on the development of new solutions and the
advancement of existing solutions.
Crescom
CEO Jae Joon Lee said, "We are very pleased and proud to introduce
Crescom's innovative musculoskeletal artificial intelligence medical software
in Seoul, the largest academic society in the Asia-Oceania region,"
adding, "Crescom will do its best to provide timely, high accuracy and
detailed analysis results in the medical field to enhance medical benefits in
Asia and global regions beyond Korea."